BioCryst Pharmaceuticals' low P/S ratio could be due to belo...

BioCryst Pharmaceuticals' low P/S ratio could be due to below-average future revenue growth. The future revenue might not justify a higher P/S, possibly straining a substantial share price increase. Some warning signs in its investment analysis are significant to consider.